Auris' Outlook Bleak In Tinnitus After Failure Of Initial Phase III Trial
Executive Summary
The Swiss biotech still holds out hope that its NMDA antagonist Keyzilen will hit its primary endpoint in a European Phase III study in acute tinnitus, but a largely US-based first Phase III trial missed both co-primary endpoints.